1-ethyl-3-[4-(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)phenyl]thiourea | 134150-39-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-ethyl-3-[4-(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)phenyl]thiourea
• CAS: 134150-39-3
• 化学式: C₁₁H₁₂N₄OS₂
• 分子量: 280.374
• InChiKey: NXLQPHHBJNNPFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.71
• 重原子数：
  18.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  65.88
• 氢给体数：
  3.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  5-(4-氨基苯基)-1,3,4-二唑-2(3H)-硫酮 、 异硫氰酸乙酯 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以75%的产率得到1-ethyl-3-[4-(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)phenyl]thiourea
  参考文献：
  名称：

  N- [4- (3H-1,3,4-oxadiazoline-2-thion-5-yl) 苯基] -N'-取代的硫脲：合成和抗微生物活性

  摘要：

  各种药理特性与 3H-1,3,4-oxadiazoline-2-thione 衍生物有关。这些包括抗惊厥 1-4) 和杀真菌 5) 特性。另一方面，硫脲衍生物具有抗植物病毒 6)、杀病毒 7)、抑制生长 8-10) 和除草剂 11) 的活性。所有这些数据促使我们将这些部分组合成一个分子。测试合成的化合物对七种微生物的抗菌活性。

  DOI：

  10.1002/ardp.19913240312

文献信息

• The structure–antituberculosis activity relationships study in a series of 5-aryl-2-thio-1,3,4-oxadiazole derivatives
  作者：Fliur Macaev、Zinaida Ribkovskaia、Serghei Pogrebnoi、Veaceslav Boldescu、Ghenadie Rusu、Nathaly Shvets、Anatholy Dimoglo、Athina Geronikaki、Robert Reynolds

  DOI：10.1016/j.bmc.2011.09.038

  日期：2011.11

  A series of 82 5-aryl-2-thio-1,3,4-oxadiazole derivatives were screened for their anti-mycobacterial activities against Mycobacterium tuberculosis H37Rv. The synthesized compounds 30-37 appeared to be the most active derivatives exhibiting more than 90% inhibition of mycobacterial growth at 12.5 mu g/mL. Structure-activity relationships study was performed for the given series by using the electronic-topological method combined with neural networks (ETM-NN). A system for the anti-mycobacterial activity prediction was developed as the result of training associative neural network (ASNN) with weights calculated from projections of a compound and each pharmacophoric fragment found on the elements of the Kohonen's self-organizing maps (SOMs). From the detailed analysis of all compounds under study, the necessary requirements for a compound to possess antituberculosis activity have been formulated. The analysis has shown that any requirement's violation for a molecule implies a considerable decrease or even complete loss of its activity. Molecular docking studies of the compounds allowed shedding light on the binding mode of these novel anti-mycobacterial inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.
• ROLLAS, SEVIM;BUYUKTIMKIN, SERVET;CEVIKBAS, ADILE, ARCH. PHARM., 324,(1991) N, C. 189-190
  作者：ROLLAS, SEVIM、BUYUKTIMKIN, SERVET、CEVIKBAS, ADILE

  DOI：——

  日期：——